This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Technicians
- Nuria Ajenjo
- Daniel Alba
- Inmaculada Almenara
- María Jesús Artiga
- Francisco De Luna
- Cecilia Sobrino
The principal objective of CNIO Biobank is to facilitate access to quality human samples and associated data for research in cancer and related diseases, ensuring that both the acquisition and their use, comply with all the legal and ethical principles that protect donors’ rights.
CNIO Biobank is a cross-service platform for CNIO researchers and the general scientific community that provides a broad service offer covering all stages in research project management requiring the use of human samples. CNIO Biobank offers: sample processing; collection management; quality, ethical and legal consultancy; acquisition and design of valuable research collections; and negotiating with different stakeholders to find suitable samples and/or help obtain ethical approval for research projects.
CNIO Biobank is authorised by the Consejería de Sanidad de la Comunidad Autónoma de Madrid (CAM) and registered in the Registro Nacional de Biobancos del Instituto de Salud Carlos III (ref. nº: B.000848).
Publications
- (2020). ACTN3 R577X Polymorphism Related to Sarcopenia and Physical Fitness in Active Older Women. Climacteric 30, 1-6. CNIO Publication.
- (2019). A Review of International Biobanks and Networks: Success Factors and Key Benchmarks-A 10-Year Retrospective Review.. Biopreservation & Biobanking 17, 512-519. CNIO Publication.
- (2019). In Search of an Evidence-Based Strategy for Quality Assessment of Human Tissue Samples: Report of the Tissue Biospecimen Research Working Group of the Spanish Biobank Network. J Transl Med 17, 370. CNIO Publication.
Open Access
- (2019). Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors. Eur J Med Chem 168, 87-109. CNIO Publication.
- (2018). In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nat Commun 9, 3501. CNIO Publication.
Open Access
- (2017). Quality Matters: 2016 Annual Conference of the National Infrastructures for Biobanking.. Biopreservation & Biobanking 15, 270-276. CNIO Publication.